RELATED STUDY
A systematic review of cannabidiol trials in neurodevelopmental disorders
Key Findings: This review of nine clinical trials that tested cannabidiol (CBD) for treating symptoms of neurodevelopmental disorders (attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), intellectual disability (ID), Tourette's syndrome (TS), and complex motor disorders (CMD) finds that the preliminary evidence is encouraging, but overall there is a lack of rigorous testing and overall inconclusive evidence for its use.
Type of Study: Clinical Meta-analysis
Study Sample Size: 9
Study Result: Positive
Study Location(s): Australia
Year of Pub: 2023
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabidivarin (CBDV)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Receptors Studied: CB1, CB2
Ligands Studied: GABA, Glutamate, Norepinephrine, Oxytocin, Serotonin, Glucocorticoid
